Fourpath Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $276K | Sell |
5,958
-16,373
| -73% | -$758K | 0.04% | 194 |
|
|
2025
Q1 | $1.36M | Sell |
22,331
-2,218
| -9% | -$135K | 0.24% | 78 |
|
|
2024
Q4 | $1.39M | Buy |
24,549
+466
| +2% | +$26.4K | 0.26% | 78 |
|
|
2024
Q3 | $1.25M | Buy |
24,083
+8,457
| +54% | +$438K | 0.23% | 83 |
|
|
2024
Q2 | $649K | Buy |
15,626
+5,219
| +50% | +$217K | 0.48% | 50 |
|
|
2024
Q1 | $564K | Buy |
+10,407
| New | +$564K | 0.39% | 61 |
|
|
2022
Q4 | – | Sell |
-4,729
| Closed | -$336K | – | 120 |
|
|
2022
Q3 | $336K | Sell |
4,729
-4,633
| -49% | -$329K | 0.23% | 85 |
|
|
2022
Q2 | $721K | Sell |
9,362
-3,729
| -28% | -$287K | 0.45% | 52 |
|
|
2022
Q1 | $956K | Buy |
13,091
+5,556
| +74% | +$406K | 0.38% | 44 |
|
|
2021
Q4 | $470K | Buy |
+7,535
| New | +$470K | 0.18% | 97 |
|